Logo image of TERN

TERNS PHARMACEUTICALS INC (TERN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TERN - US8808811074 - Common Stock

29.36 USD
+2.23 (+8.22%)
Last: 12/5/2025, 8:00:00 PM
29.49 USD
+0.13 (+0.44%)
After Hours: 12/5/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, TERN scores 3 out of 10 in our fundamental rating. TERN was compared to 191 industry peers in the Pharmaceuticals industry. While TERN has a great health rating, there are worries on its profitability. TERN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TERN has reported negative net income.
TERN had a negative operating cash flow in the past year.
In the past 5 years TERN always reported negative net income.
TERN had a negative operating cash flow in each of the past 5 years.
TERN Yearly Net Income VS EBIT VS OCF VS FCFTERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

TERN has a Return On Assets of -31.31%. This is comparable to the rest of the industry: TERN outperforms 51.04% of its industry peers.
TERN has a Return On Equity (-33.24%) which is in line with its industry peers.
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROIC N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
TERN Yearly ROA, ROE, ROICTERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TERN Yearly Profit, Operating, Gross MarginsTERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for TERN has been increased compared to 1 year ago.
Compared to 5 years ago, TERN has more shares outstanding
TERN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TERN Yearly Shares OutstandingTERN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TERN Yearly Total Debt VS Total AssetsTERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TERN has an Altman-Z score of 87.89. This indicates that TERN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TERN (87.89) is better than 97.92% of its industry peers.
There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.89
ROIC/WACCN/A
WACCN/A
TERN Yearly LT Debt VS Equity VS FCFTERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 19.52 indicates that TERN has no problem at all paying its short term obligations.
TERN has a better Current ratio (19.52) than 89.06% of its industry peers.
TERN has a Quick Ratio of 19.52. This indicates that TERN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 19.52, TERN belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52
TERN Yearly Current Assets VS Current LiabilitesTERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

TERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.71%, which is quite good.
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.72% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.5%
EPS Next 2Y-8.95%
EPS Next 3Y-11.67%
EPS Next 5Y-3.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TERN Yearly Revenue VS EstimatesTERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
TERN Yearly EPS VS EstimatesTERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TERN. In the last year negative earnings were reported.
Also next year TERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TERN Price Earnings VS Forward Price EarningsTERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TERN Per share dataTERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

TERN's earnings are expected to decrease with -11.67% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.95%
EPS Next 3Y-11.67%

More info and screens

0

5. Dividend

5.1 Amount

TERN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (12/5/2025, 8:00:00 PM)

After market: 29.49 +0.13 (+0.44%)

29.36

+2.23 (+8.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners94.22%
Inst Owner Change5.46%
Ins Owners0.26%
Ins Owner Change7.02%
Market Cap2.64B
Revenue(TTM)N/A
Net Income(TTM)-94.44M
Analysts84.71
Price Target31.05 (5.76%)
Short Float %11.08%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.4%
Min EPS beat(2)10.7%
Max EPS beat(2)12.1%
EPS beat(4)4
Avg EPS beat(4)13.96%
Min EPS beat(4)8.96%
Max EPS beat(4)24.07%
EPS beat(8)8
Avg EPS beat(8)12.04%
EPS beat(12)10
Avg EPS beat(12)9.13%
EPS beat(16)14
Avg EPS beat(16)10.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)92.36%
PT rev (3m)67.15%
EPS NQ rev (1m)1.15%
EPS NQ rev (3m)1.55%
EPS NY rev (1m)4.22%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.31
P/tB 9.31
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -0.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.52
Quick Ratio 19.52
Altman-Z 87.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)29.77%
Cap/Depr(5y)60.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
EPS Next Y2.5%
EPS Next 2Y-8.95%
EPS Next 3Y-11.67%
EPS Next 5Y-3.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.92%
EBIT Next 3Y-16.74%
EBIT Next 5Y-3.39%
FCF growth 1Y-31.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.76%
OCF growth 3YN/A
OCF growth 5YN/A

TERNS PHARMACEUTICALS INC / TERN FAQ

Can you provide the ChartMill fundamental rating for TERNS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TERN.


What is the valuation status for TERN stock?

ChartMill assigns a valuation rating of 0 / 10 to TERNS PHARMACEUTICALS INC (TERN). This can be considered as Overvalued.


How profitable is TERNS PHARMACEUTICALS INC (TERN) stock?

TERNS PHARMACEUTICALS INC (TERN) has a profitability rating of 1 / 10.


How financially healthy is TERNS PHARMACEUTICALS INC?

The financial health rating of TERNS PHARMACEUTICALS INC (TERN) is 8 / 10.